Investors have been drawn to Xencor’s remarkable scientific capabilities around protein engineering and our broad intellectual property, which serve as the engine behind our XmAb® drug development programs. We engineer monoclonal antibodies and develop them in clinical studies for the potential treatment of patients with cancer and autoimmune diseases. Our XmAb technologies, consisting of small changes to the structure of monoclonal antibodies, enable new mechanisms of therapeutic action.

We have built a clinical pipeline of novel bispecific antibodies using our XmAb bispecific Fc domain, including several bispecific T-cell engagers (TCEs). In oncology applications, these molecules bind to a tumor-associated antigen on cancer cells and to cytotoxic T cells, leading to the targeted killing of tumor cells by the immune system. We are also advancing TCEs that deplete B cells for the treatment of autoimmune diseases, and two programs are currently in development.

Our TL1A programs are led by XmAb942, a novel high-potency anti-TL1A antibody designed for extended half-life, in Phase 1 development for the treatment of patients with inflammatory bowel disease.

The plug-and-play nature of XmAb Fc domains enables us to selectively provide access and license one or more XmAb technologies for our collaborators’ use in developing their own proprietary antibodies with improved properties. Candidates engineered with our XmAb technologies are in clinical development internally and with partners, including Amgen and J&J Innovative Medicine, among others. Three marketed XmAb medicines have been developed with our protein engineering technologies.